Streetbeat News

LRMR

Larimar Therapeutics, Inc.

https://www.larimartx.com

Industry

Biotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Open

3.33

Mkt cap

204M

Volume

514K

High

3.35

P/E Ratio

-2.77

52-wk high

12.91

Low

3.17

Div yield

N/A

52-wk low

3.01

Larimar Therapeutics has begun dosing adolescents in a pediatric pharmacokinetic study for Friedreich's ataxia, marking a significant step in their clinical development efforts.

Portfolio Pulse from

January 23, 2025 | 9:15 pm

Larimar Therapeutics reported positive initial data from a phase 2 study using nomlabofusp for Friedreich's Ataxia, showing increased tissue FXN protein levels. The Friedreich's Ataxia market is projected to grow significantly by 2030, with more data expected in 2025.

Portfolio Pulse from

January 03, 2025 | 11:00 pm

Larimar Therapeutics announced positive initial data from its ongoing long-term open-label extension study for nomlabofusp, a treatment for Friedreich's Ataxia. The study involves daily subcutaneous injections and shows promising results.

Portfolio Pulse from

December 16, 2024 | 12:15 pm

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating for Larimar Therapeutics (NASDAQ:LRMR) and maintained a price target of $15.